Beam Therapeutics (NASDAQ:BEAM) executives and clinical collaborators presented updated top-line data from the company’s ...

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and ...

Beam Therapeutics has set its sights on an accelerated approval of its base editing therapy for the severe form of alpha-1 ...

Beam Therapeutics (NASDAQ:BEAM) gains attention as Nasdaq futures reflect biotech valuation shifts and target revisions.

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, ...

Beam Therapeutics (BEAM) stock jumps as the company seeks to move gene-editing drug BEAM-302 to pivotal study in.alpha-1 ...

Beam Therapeutics Inc. (NASDAQ:BEAM) rose 8% Tuesday after announcing updated clinical data from its ongoing Phase 1/2 trial ...

Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) gained about 8% on Wednesday after the company released updated results from ...

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins ...

BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.